Cancer Care Ontario | Cancer Care Ontario

You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.

Skip to main content Skip to search

4 Results

Guidelines and Advice

Use of the Epidermal Growth Factor Receptor Inhibitors Gefitinib (Iressa®), Erlotinib (Tarceva®), Afatinib, Dacomitinib or Icotinib in the Treatment of Non–SmallCell Lung Cancer: A Clinical Practice Guideline

Status: In-Review
ID: 7-9
Version: 2

Apr 2014

Guidelines and Advice

Neoadjuvant and adjuvant systemic therapy for newly diagnosed stage II, III, or IV epithelial ovary, fallopian tube, or primary peritoneal carcinoma

Status: Current
ID: GL 4-1
Version: 2

Jan 2021

Guidelines and Advice

Position Statements for Nursing Practice in Cancer Care

Status: Current
Version: 2

May 2021

Guidelines and Advice

Systemic therapy of denosumab in altering surgical outcomes in patients with giant cell tumour of bone

Status: Current
ID: ES 11-13

Feb 2021